Table 4.
Univariate model analyses of factors predictive of positive DECT result
| OR (95% CI) | p | |
|---|---|---|
| Gender (reference: male gender) | 0.48 (0.24–0.99) | 0.04 |
| Body mass index (per kg/m2) | 1.03 (0.96–1.11) | 0.36 |
| Cardiovascular disease yes/no | 2.72 (1.36–5.42) | 0.04 |
| Diabetes mellitus yes/no | 3.69 (1.26–10.71) | 0.01 |
| Urate lowering therapy use at the moment of DECT yes/no | 2.6 (1.15–6.28) | 0.02 |
| Disease duration years | 1.01 (1.005–1.02) | 0.01 |
| Frequency of attacks per year | 1.2 (1.08–1.33) | 0.01 |
| Uric acid levels between flares (per μmol/l) | 1.004 (1.001–1.007) | 0.008 |
| Creatinine clearance (per ml/min) | 0.95 (0.92–0.99) | 0.01 |
| Joint involvement at the moment of DECT: MTP1 or other joints | 1.69 (1.05–3.37) | 0.1 |
| Past first metatarsophalangeal (MTP1) joint involvement yes/no | 3.37 (1.69–6.72) | 0.01 |
| MSU crystals at microscopy yes/no | 1.62 (1.23–2.17) | 0.001 |